MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

Search

Evotec AG

Cerrado

SectorFinanzas

5.9 -0.51

Resumen

Variación precio

24h

Actual

Mínimo

5.75

Máximo

6.08

Métricas clave

By Trading Economics

Ingresos

55M

-40M

Ventas

2.8M

185M

Margen de beneficios

-21.437

Empleados

5,007

EBITDA

58M

-45M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+116.95% upside

Dividendos

By Dow Jones

Próximas Ganancias

17 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.1B

Apertura anterior

6.41

Cierre anterior

5.9

Noticias sobre sentimiento de mercado

By Acuity

27%

73%

89 / 542 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Evotec AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 jun 2024, 13:17 UTC

Charlas de Mercado

Evotec's Profit Outlook Looks Gloomy -- Market Talk

Comparación entre iguales

Cambio de precio

Evotec AG previsión

Precio Objetivo

By TipRanks

116.95% repunte

Estimación a 12 Meses

Media 12.8 EUR  116.95%

Máximo 14 EUR

Mínimo 11.6 EUR

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Evotec AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

5.76 / 6.075Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

89 / 542 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Evotec AG

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.